Nevertheless, whether SAH-mAH2-5 can present identical or similar antitumor effects in vivo or whether it is also effective for hematological malignancies that are mostly caused by Notch1 gain-of-function mutations needs further validation. Here, NOTCH1 is linked to hematologic disorder.